Safety, efficacy, and analysis of key parameters after prophylactic administration of a sustained-release formulation of azithromycin in lung cancer surgery

Taniguchi, Daisuke; Watanabe, Hironosuke; Morinaga, Yoshitomo; Sasaki, Daisuke; Matsuda, Junichi; Sato, Shuntaro; Kaku, Norihito; Miyazaki, Takuro; Matsumoto, Keitaro; Tsuchiya, Tomoshi; Sakaeda, Toshiyuki; Yanagihara, Katsunori; Nagayasu, Takeshi

doi:10.21037/apm-21-383

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical settings, the pharmacokinetic properties of AZI, such as good oral bioavailability, a longer half-life and low clearance, are appreciated. Likewise, the safety and tolerability of patients with different pathological backgrounds make AZI a valuable option for the treatment of various infections [6,9,[11][12][13].…”

Section: Introductionmentioning

confidence: 99%

A mini‐review on anticancer‐related properties of azithromycin and its potential activities in overcoming the challenges of glioblastoma

Hassan

Yusoff

Idris

et al. 2023

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

The resistance, plasticity and heterogeneity of cancer cells, including glioblastoma (GB) cells, have prompted the investigation of various agents for possible adjuncts and alternatives to existing therapies. This includes a macrolide antibiotic, azithromycin (AZI). It possesses intriguing anticancer properties in a range of cancer models in vitro, such as antiproliferative, pro‐apoptotic, anti‐autophagy and anti‐angiogenic effects. In fact, AZI is renowned for its ability to eradicate cancer stem cells by inhibiting mitochondrial biogenesis and respiration. AZI‐containing regimens in cancer patients for different purposes have shown favourable (i.e., attributed to its antibacterial activity) and unfavourable outcomes. Whilst its direct anticancer effects have yet to be clinically proven. To that end, this review provides a summary of AZI anticancer studies and delineates its potential activities in overcoming the challenges of GB.

show abstract

Section: Introductionmentioning

confidence: 99%

A mini‐review on anticancer‐related properties of azithromycin and its potential activities in overcoming the challenges of glioblastoma

Hassan

Yusoff

Idris

et al. 2023

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis

Zhao,

Yua

2024

THC

View full text Add to dashboard Cite

BACKGROUND: Lung cancer (LC) is one of the leading causes of death worldwide. Treatment methodologies such as chemotherapy and radiotherapy have improved patient survival rates. Nevertheless, these treatments can also lead to adverse reactions and impact patients’ nutritional status and quality of life (QOL). Antibiotics are commonly used for treating infections, but there is still controversy regarding their potential adverse effects on LC patients. OBJECTIVE: This work aimed to investigate the impact of antibiotic adoption on the nutritional status and QOL of LC patients undergoing radiotherapy or chemotherapy, providing valuable insights for the clinical management of LC. METHODS: A meta-analysis approach was employed to comprehensively evaluate the relationship by synthesizing relevant literature. Published studies were identified through searches in databases such as PubMed, EMBASE, Cochrane Library, Web of Science, and CNKI. The inclusion criteria encompassed randomized controlled trials, cohort studies, and cross-sectional studies. Assessment indicators included patient weight, BMI, hemoglobin levels, and QOL. Meta-analysis was conducted using software such as the Cochrane Collaboration and RevMan5.3. Heterogeneity was evaluated using the Higgins I2 index, where values between 25% and 50% indicate moderate heterogeneity, and values greater than 50% indicate substantial heterogeneity. RESULTS: 12 eligible studies involving 1,917 patients were finally included. LC patients who received antibiotics during radiotherapy or chemotherapy were found to have a higher risk of malnutrition. The antibiotic group exhibited a more significant decrease in body mass index (BMI) (P< 0.05) and lower serum albumin levels (P< 0.05) versus the control (C) group. Additionally, the overall QOL scores in the antibiotic group were dramatically lower than those in the C group, showing a significant difference with P< 0.05. Sensitivity analysis indicated that the overall conclusions of this work were robust and unbiased. CONCLUSION: Antibiotics in LC patients undergoing radiotherapy or chemotherapy may increase the risk of malnutrition and decrease their QOL. Hence, physicians should carefully consider antibiotics and take necessary preventive measures and supportive treatments to improve LC patients’ nutritional status and QOL.

show abstract

Safety, efficacy, and analysis of key parameters after prophylactic administration of a sustained-release formulation of azithromycin in lung cancer surgery

Cited by 2 publications

References 31 publications

A mini‐review on anticancer‐related properties of azithromycin and its potential activities in overcoming the challenges of glioblastoma

A mini‐review on anticancer‐related properties of azithromycin and its potential activities in overcoming the challenges of glioblastoma

Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis

Contact Info

Product

Resources

About